Women and clinicians are regularly reminded about the threat of breast cancer by the media, advertisements, and the experiences of friends or family members who are fighting the disease. And there is good reason for breast cancer to be prominent in our
Read More
Researchers who study the influence of hormones on behavior have the greatest difficulty in associating testosterone with any human behaviors whatsoever. They have injected all kinds of animals at all stages of development with synthetic testosterone to see how it affected their
Read More
In the recently published analysis of the effects of estrogen plus progestin on health-related quality of life (QOL) in the Women’s Health Initiative (WHI), the authors concluded that this therapy did not have a clinically meaningful effect.1 However, caution is warranted in
Read More
Holmberg and Anderson recently published a research letter in the journal Lancet regarding early cessation of the HABITS study,1 a Scandinavian trial designed to evaluate the risk of breast cancer recurrence in women with previously treated breast cancers who were given hormone
Read More
Children, old people and women are all short of testosterone. Even ten years ago, testosterone was a word not often heard; nowadays the presence of testosterone in the environment is often remarked on. When the stands at the football ground are packed
Read More
Women with a history of breast cancer have been advised to avoid estrogen replacement therapy (ERT). A reassessment of this approach has been initiated by several authors and clinical reports to date have not supported this tenet. The only prospective randomized trial
Read More
The original intention of testosterone were the treatment of males who have too little or no natural endogenous testosterone production with hypogonadism. Appropriate use for this purpose is legitimate hormone replacement therapy which maintains serum testosterone levels in the normal range. Many
Read More
Baseline incidence of invasive breast cancers in non-HRT users is 32/1000 between ages 50 and 65 years. Baseline incidence of endometrial cancers in non-HRT users is 5/1000 between ages 50 and 64 years. The excess risk of breast cancer with long-term use
Read More
The effects of estrogen deficiency on the skeletal system have been clearly established for more than 60 years. The molecular mechanisms accounting for estrogen-related bone loss have been known for a decade or longer, and the benefits of estrogen on the skeleton
Read More
Menopause-related estrogen loss is associated with symptoms that can have a negative impact on a woman’s sense of well-being and her daily activities. In addition, menopausal women are at an increased risk for developing osteoporosis. Therefore, for some menopausal women, hormone therapy
Read More